Rhenman & Partners Asset Management Ab Merus N.V. Transaction History
Rhenman & Partners Asset Management Ab
- $766 Million
- Q2 2025
A detailed history of Rhenman & Partners Asset Management Ab transactions in Merus N.V. stock. As of the latest transaction made, Rhenman & Partners Asset Management Ab holds 116,000 shares of MRUS stock, worth $10.9 Million. This represents 0.8% of its overall portfolio holdings.
Number of Shares
116,000
Previous 74,500
55.7%
Holding current value
$10.9 Million
Previous $3.14 Million
94.61%
% of portfolio
0.8%
Previous 0.37%
Shares
4 transactions
Others Institutions Holding MRUS
# of Institutions
217Shares Held
65.3MCall Options Held
311KPut Options Held
556K-
Paradigm Biocapital Advisors LP New York, NY4.28MShares$403 Million10.51% of portfolio
-
Rtw Investments, LP New York, NY4MShares$377 Million3.23% of portfolio
-
Wellington Management Group LLP Boston, MA3.73MShares$351 Million0.04% of portfolio
-
Commodore Capital LP New York, NY3.53MShares$332 Million17.29% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.38MShares$319 Million4.09% of portfolio
About Merus N.V.
- Ticker MRUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,878,200
- Market Cap $4.32B
- Description
- Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...